On May 27-28 2024, the second progress meeting of the MTBVACN3 project took place in Pilanesberg, near Johannesburg in South Africa. During these days the consortium partners met to share experiences and review the progress of the study after one year of the start of recruitment. They got the opportunity to visit Wits Vida and gain insight into their facilities. To date, 2,300 infants 
have been vaccinated across the 6 recruiting centers. The MTBVACN3 phase 3 efficacy trial aims to evaluate the efficacy, safety, and immunogenicity of the vaccine administered in Healthy HIV Unexposed and HIV-Exposed Uninfected Newborns in tuberculosis (TB)-endemic regions of sub-Saharan Africa such as South Africa, Senegal and Madagascar. MTBVAC is one of the promising TB vaccine candidates for newborns. The target is to vaccinate 7,120 newborns against tuberculosis during their first week of life.